ANTHEM BIOSCIENCES LTD
Quality (85/100) does the heavy lifting; valuation (1/100) is the drag.
ExpensiveOvervaluedStocksWizard rates ANTHEM BIOSCIENCES LTD a Sell, scoring 43/100 on our blended model. At ₹809.2 it trades above our blended DCF and relative-multiples fair value of ₹404.6, about 50% downside to that estimate — we read it as overvalued by 50%. On 76.2x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 6% below its 52-week high of ₹862.25 and 37% above the low of ₹590.86. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9. The average analyst target of ₹886.57 implies about 10% upside across 7 analysts. It clears 7 of 11 investability checks, with durability 85, valuation 1 and momentum 76 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹323.68.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-6.15% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell43Piotroski F-score 7/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- No data: ROE above 15%
- Pass: Low debt (D/E < 0.5): 0.02x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -23%
- Fail: Earnings growing: -13%
- Pass: Net margin ≥ 10%: 28.7%
- No data: Current ratio > 1.5
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 69.23
- Pass: Piotroski ≥ 7: 7/9
Quarterly results
Annual financials
Shareholding
- Promoter84.2%
- Institutions12.3%
- Public & other3.5%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (28.7%).
- Financially solid — Altman Z 69.23.
- High Piotroski quality score (7/9).
Bear case
Threats
- Earnings contracting year on year.
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About ANTHEM BIOSCIENCES LTD
Anthem Biosciences Limited is a technology-focused contract research, development, and manufacturing organization operating through two segments: CRDMO services and Speciality Ingredients. The company provides end-to-end services across new chemical entity and new biological entity lifecycles, spanning target identification, concept stage, preclinical development, and manufacturing development batches.
ANTHEM BIOSCIENCES LTD — frequently asked questions
Is ANTHEM BIOSCIENCES LTD a buy, hold or sell?
StocksWizard currently rates ANTHEM BIOSCIENCES LTD (ANTHEM) a Sell, based on a blended score of 43/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is ANTHEM BIOSCIENCES LTD's fair value?
Our blended DCF and relative-valuation model estimates ANTHEM BIOSCIENCES LTD's fair value at about ₹404.6, versus a current price of ₹809.2 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is ANTHEM BIOSCIENCES LTD financially healthy?
ANTHEM BIOSCIENCES LTD scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9.
How has ANTHEM BIOSCIENCES LTD's share price performed?
ANTHEM BIOSCIENCES LTD is up 6% over three months, and last traded at ₹809.2. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.